Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Jan 02, 2022 1:08pm
248 Views
Post# 34277366

RE:RE:RE:RE:RE:RE:RE:Dr. Vera's Move

RE:RE:RE:RE:RE:RE:RE:Dr. Vera's Move

The procedure is very simple to do and as a matter of fact they train docs online and I think they may even guide them live during procedure  Once learned it is easy to do.  The only error was in protocol at beginning on 1st 12 patients of trial where they used average bladder volume instead of maximum bladder volume.  Now that this has been corrected, I'm hopeful that a large majority of patients will be CR as we are seeing in PH2 with Optimized treated patients where max bladder volume is used  IMO Next data readout could be epic if we see 4 or more of 7 patients CR. ( ideally 5 or more, but even with 4 we are beating single agent competitors)  IMO


Impalaman wrote: The Dr. who did # 5 and 6----must have known how to use the equipment properly----and 1433 did the rest----I've always had a concern that different Doc. could effect the out comes of patients---etc.--PR----and no response patients.---but that's just me.----any thoughts on that enriq.

 

<< Previous
Bullboard Posts
Next >>